SOST (Sclerostin), RANKL, and LRP5/WNT Signaling in Bone Homeostasis

SOST (Sclerostin), RANKL, and LRP5/WNT Signaling form the mechanosensitive biochemical circuit that continuously remodels the vertebrate skeleton, replacing roughly 10% of adult human bone mass each year through the coupled action of bone-forming osteoblasts (mesenchymal lineage) and bone-resorbing osteoclasts (hematopoietic monocyte/macrophage lineage). Orchestrating both lineages are osteocytes—terminally differentiated osteoblasts entombed within fluid-filled mineralized lacunae and interconnected by 50 to 100 dendritic processes coursing through microscopic canaliculi (~90–95% of all cells in adult bone). By sensing interstitial fluid shear stress during mechanical loading, osteocytes control two antagonistic paracrine pathways: the osteoanabolic canonical WNT–LRP5/LRP6–β-catenin pathway (inhibited by osteocyte-secreted sclerostin, encoded by SOST on chromosome 17q21.31) and the osteocatabolic RANKL–RANK–osteoprotegerin (OPG) osteoclastogenesis axis.

Rare human Mendelian bone dysplasias provided the blueprint for modern osteoporosis drug discovery. Loss-of-function mutations in SOST (causing sclerosteosis and Van Buchem disease) or gain-of-function missense mutations in LRP5 (p.Gly171Val, causing autosomal dominant high-bone-mass syndrome) produce dense, fracture-resistant skeletons (bone mineral density Z-scores +5 to +12 SD) by unleashing osteoblast WNT signaling. Conversely, biallelic loss of LRP5 causes osteoporosis-pseudoglioma syndrome (OPPG) with childhood fractures, while loss of the decoy receptor osteoprotegerin (TNFRSF11B) causes juvenile Paget disease. These genetic discoveries directly yielded two transformative monoclonal antibody therapeutics: denosumab (Prolia / Xgeva, neutralizing RANKL) and romosozumab (Evenity, neutralizing sclerostin to simultaneously stimulate bone formation and suppress bone resorption).

LRP5 β-Propeller Architecture and High-Bone-Mass (Gly171Val) Mutations

On the plasma membrane of osteoprogenitors and mature osteoblasts, canonical WNT ligands (WNT1, WNT3A, WNT7B, WNT10B) assemble a ternary signaling complex with a seven-transmembrane Frizzled (FZD) receptor and one of two single-pass low-density lipoprotein receptor-related co-receptors: LRP5 (Chr11q13.2, 1,615 amino acids) or LRP6 (Chr12p13.2, 1,613 amino acids). The extracellular domain of LRP5/LRP6 consists of four tandem six-bladed β-propeller (YWTD)–epidermal growth factor (EGF) modules (E1–E4) followed by three LDLR type A repeats. When WNT bridges FZD and LRP5/LRP6, casein kinase 1γ (CK1γ) and glycogen synthase kinase-3β (GSK-3β) phosphorylate five reiterated PPPSPxS motifs on the cytoplasmic tail of LRP5/LRP6. These phosphorylated motifs trap Axin1 and inhibit the cytoplasmic β-catenin destruction complex (APC–Axin–GSK-3β–CK1α), allowing unphosphorylated β-catenin (CTNNB1) to accumulate, translocate into the nucleus, and co-activate TCF/LEF transcription factors. In osteoblasts, nuclear β-catenin upregulates RUNX2, osterix (SP7), type I collagen (COL1A1), alkaline phosphatase (ALPL), and osteoprotegerin (OPG / TNFRSF11B).

In 2001–2002, human genetic linkage studies revealed that reciprocal mutations in LRP5 drive opposite extremes of human bone mass:

1. Autosomal Recessive Loss-of-Function (OPPG): Frameshift and nonsense mutations in LRP5 abolish osteoblast WNT signaling and retinal vascularization, causing osteoporosis-pseudoglioma syndrome (lumbar spine BMD Z-score −4 to −6 SD, childhood vertebral compression fractures, and persistent fetal ocular hyaloid vasculature).
2. Autosomal Dominant Gain-of-Function (High-Bone-Mass Syndrome): Heterozygous missense variants clustering inside the first YWTD β-propeller (E1) of LRP5—most famously p.Gly171Val (G171V), p.Ala214Thr, and p.Gly171Arg—leave WNT binding intact while sterically abolishing binding of the endogenous extracellular WNT antagonists Sclerostin (SOST) and Dickkopf-1 (DKK1). Without SOST/DKK1 inhibition, LRP5-G171V osteoblasts remain constitutively responsive to WNT, producing cortical and trabecular bone mineral density 5 to 8 standard deviations above the population mean with near-total resistance to skeletal fractures.

Sclerostin Structure (NXI Motif), Sclerosteosis, and the 52-kb ECR5 Enhancer

Encoded by the 2-exon SOST gene on chromosome 17q21.31 (213 amino acids; 190-aa mature secreted glycoprotein of ~24 kDa), sclerostin is synthesized almost solely by mature, mineral-embedded osteocytes. Structurally, NMR and X-ray crystallography show that sclerostin folds into a three-loop cystine-knot (DAN family) core stabilized by three intramolecular disulfide bonds, flanked by flexible N- and C-terminal arms. Protruding from the tip of Loop 2 (residues 86–111) is a conserved Asn93–Ala94–Ile95 (NAI / NXI) motif that plugs directly into the central acidic pocket on the top face of the first β-propeller (E1) of LRP5 and LRP6 (K_d ≈ 2–5 nM), while a positively charged patch on sclerostin binds LRP4 (an osteoblast chaperone that concentrates sclerostin at the membrane). By occupying LRP5/LRP6 E1, sclerostin competitively displaces WNT1/WNT10B and induces LRP5/LRP6 internalization.

When mechanical loading (weight-bearing exercise) bends bone matrix, fluid shear stress through osteocyte canaliculi triggers Piezo1 mechanosensitive Ca²⁺ channels, prostaglandin E₂ (PGE₂), and nitric oxide release, which suppresses SOST transcription via histone deacetylase HDAC4/HDAC5 inhibition of the transcription factor MEF2C, locally unleashing osteoblast bone formation along the stressed cortex. Conversely, microgravity (spaceflight) or immobilization upregulates SOST expression, driving disuse osteoporosis. Two ultra-rare genetic disorders confirmed SOST as a premier drug target: Sclerosteosis (caused by biallelic coding nonsense or splice mutations in SOST, prevalent in the Afrikaner population of South Africa) and Van Buchem disease (caused by a homozygous 52-kb non-coding deletion located 35 kb downstream of SOST in a Dutch founder isolate that deletes the ECR5 bone-specific enhancer Containing the MEF2C binding site). Importantly, heterozygous carriers of SOST mutations have elevated bone mineral density and low fracture rates with zero skeletal overgrowth or cranial nerve compression, inspiring the humanized anti-sclerostin monoclonal antibody romosozumab (Evenity).

Osteoclastogenesis via RANK–TRAF6–NFATc1 and Decoy Blockade by OPG

While WNT–LRP5/LRP6 controls bone formation, bone resorption is governed by the RANKL–RANK–OPG cytokine triad. Osteocytes and bone-marrow stromal/osteoblast cells express receptor activator of nuclear factor-κB ligand (RANKL, encoded by TNFSF11 on Chr13q14.11) as a homotrimeric transmembrane and matrix-metalloproteinase-cleaved soluble protein. When RANKL (paired with macrophage colony-stimulating factor, M-CSF / CSF1) binds its trimeric receptor RANK (TNFRSF11A on Chr18q21.33) on hematopoietic monocyte/macrophage precursors, the cytoplasmic tail of RANK recruits the E3 ubiquitin ligase adaptor TRAF6. TRAF6 activates NF-κB, MAPK (JNK/p38), and Ca²⁺/calmodulin-dependent calcineurin signaling to induce the master transcription factor NFATc1 (nuclear factor of activated T-cells, cytoplasmic 1). NFATc1 drives precursor cell-cell fusion (DC-STAMP) into giant multinucleated osteoclasts and upregulates the ruffled-border proton pump (TCIRG1 V-ATPase), chloride channel CLCN7, and cathepsin K (CTSK), which acidify the resorption lacuna (pH ~4.5) to dissolve hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂) and digest Type I collagen.

To prevent runaway osteolysis, canonical WNT/β-catenin and estrogen (ESR1) signaling in osteoblasts induce secretion of osteoprotegerin (OPG, encoded by TNFRSF11B on Chr8q24.12), a soluble homodimeric TNF-receptor decoy lacking a transmembrane domain that binds RANKL with picomolar affinity, sterically blocking RANKL–RANK engagement. After menopause, declining 17β-estradiol levels lower OPG and elevate osteocyte RANKL and SOST, tipping the remodeling balance toward net bone loss.

Romosozumab vs Denosumab: Uncoupling Formation from Resorption

Traditional antiresorptive therapies (bisphosphonates such as alendronate/zoledronate and the anti-RANKL human IgG2 monoclonal antibody denosumab) potently suppress osteoclast resorption (reducing serum C-telopeptide CTX by >80%), but because osteoclasts normally release matrix-bound coupling factors (TGF-β, IGF-1) that recruit osteoblasts, antiresorptives secondarily suppress osteoblast bone formation (P1NP falls in parallel). Conversely, parathyroid hormone receptor (PTH1R) agonists (teriparatide, abaloparatide) stimulate osteoblast formation (+P1NP) but secondarily upregulate RANKL to increase resorption (+CTX, limiting the anabolic window).

By neutralizing sclerostin (Loop 2), romosozumab (Evenity) achieves true uncoupling ("dual-action" pharmacology):

1. Direct Osteoanabolic Surge (+P1NP): Releasing LRP5/LRP6 from sclerostin inhibition activates canonical WNT/β-catenin in osteoprogenitors and quiescent bone-lining cells, driving a +100% to +150% surge in the bone-formation marker P1NP and stimulates modeling-based bone formation on both trabecular and periosteal surfaces.
2. Simultaneous Antiresorptive Suppression (−CTX): Because nuclear β-catenin in osteoblasts and osteocytes directly transcribes TNFRSF11B (OPG) while suppressing RANKL, romosozumab elevates the local OPG : RANKL ratio, reducing serum CTX bone resorption by ~30% to 40% throughout the 12-month treatment course—producing a 13.3% gain in lumbar spine BMD in just 1 year (FRAME and ARCH Phase 3 trials) before transitioning to denosumab or bisphosphonates to lock in the newly mineralized matrix.

How does the LRP5 Gly171Val mutation cause high bone mass without increasing WNT ligand levels?

The p.Gly171Val (G171V) missense mutation lies inside the central pocket of the first β-propeller (E1) of the LRP5 extracellular domain. While WNT ligands still bind LRP5-G171V and Frizzled normally, the bulky valine side chain sterically blocks the NAI (NXI) motif of the endogenous inhibitors sclerostin (SOST) and Dickkopf-1 (DKK1) from docking onto LRP5, leaving osteoblast WNT/β-catenin signaling constitutively uninhibited (BMD Z-scores +5 to +8).

What is the genetic and molecular difference between Sclerosteosis and Van Buchem disease?

Both autosomal recessive high-bone-mass disorders result from deficiency of osteocyte sclerostin, but Sclerosteosis is caused by biallelic coding nonsense or splice-site mutations within the 2 exons of the SOST gene (completely eliminating sclerostin protein and occasionally causing syndactyly), whereas Van Buchem disease is caused by a homozygous 52-kb non-coding deletion located 35 kb downstream of SOST that removes the bone-specific ECR5 enhancer (MEF2C binding site), silencing postnatal osteocyte SOST transcription while sparing embryonic limb-bud expression.

Why does romosozumab simultaneously increase bone formation and decrease bone resorption, whereas teriparatide increases both?

Teriparatide (PTH 1–34) activates PTH1R–cAMP–PKA in osteoblasts to stimulate bone formation, but also directly induces RANKL transcription, which secondarily recruits osteoclasts and accelerates bone resorption. In contrast, romosozumab neutralizes sclerostin to activate canonical WNT–LRP5/β-catenin signaling, which not only drives osteoblast bone formation (+P1NP) but also directly activates transcription of osteoprotegerin (OPG), the endogenous decoy receptor that neutralizes RANKL and suppresses osteoclast resorption (−CTX).

1. Brunkow, M. E., Gardner, J. C., Van Ness, J., et al. (2001). "Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein." American Journal of Human Genetics, 68(3), 577–589. https://doi.org/10.1086/318811
2. Boyden, L. M., Mao, J., Belsky, J., et al. (2002). "High bone density due to a mutation in LDL-receptor-related protein 5." New England Journal of Medicine, 346(20), 1513–1521. https://doi.org/10.1056/NEJMoa013444
3. Cummings, S. R., San Martin, J., McClung, M. R., et al. (2009). "Denosumab for prevention of fractures in postmenopausal women with osteoporosis." New England Journal of Medicine, 361(8), 756–765. https://doi.org/10.1056/NEJMoa0809493
4. Cosman, F., Crittenden, D. B., Adachi, J. D., et al. (2016). "Romosozumab treatment in postmenopausal women with osteoporosis." New England Journal of Medicine, 375(16), 1532–1543. https://doi.org/10.1056/NEJMoa1607948